trading - Pharma Value

Timing of access to drugs and advanced therapies (ATMP) for ultra-rare diseases

On Tuesday 29 November 2022, Ginevra Mastroianni, Institutional and Regulatory Affairs Specialist at Pharma Value, presented at the 8th National Congress of ISPOR Italy - Rome Chapter a

Appeal by Bayer VS Ministry of Health, MEF and AIFA on the new P&R criteria - Council of State ruling

On 7 January 2022, the Council of State (15 March 2021, No. 3095) issued its judgment on the appeal filed by Bayer against the

Highlights on the AIFA Pricing Guidelines

The AIFA Guidelines for the compilation of the dossier supporting the application for the reimbursability and pricing of a medicine have finally been published

negotiation

Timing of access to drugs and advanced therapies (ATMP) for ultra-rare diseases

Appeal by Bayer VS Ministry of Health, MEF and AIFA on the new P&R criteria - Council of State ruling

Highlights on the AIFA Pricing Guidelines